Biopharma Peg Assists Adc Development Articles & Analysis
9 articles found
Recombinant protein expression is a cornerstone of modern biopharmaceutical development, providing the means to produce proteins with therapeutic potential, enzymes, and antibodies. Among various expression systems, Chinese Hamster Ovary (CHO) cells have emerged as the preferred choice for many researchers and pharmaceutical companies. This article delves into the significance of recombinant ...
Peptide drugs are bioactive molecules formed by connecting multiple amino acids through peptide bonds. Generally, they are formed by connecting 10-100 amino acids, with a relative molecular mass lower than 10000. Most peptide drugs come from endogenous peptides or natural peptides, so they have no or little side effects on the human body. Compared to protein drugs, peptide drugs also have ...
Bioproduction is a critical element in the creation of many vaccines, therapeutics, and other biopharmaceuticals. A central facet of this process involves the development of stable cell lines that are capable of producing these vital products in abundance and with consistency. This article will explore the in-depth process and importance of stable cell line development in bioproduction. The ...
Host cell proteins (HCPs) are process-related impurities produced by host cells and are typically present at low levels in recombinant biopharmaceutical products. Enzyme-linked immunosorbent assay (ELISA) has traditionally been used to monitor the total content of HCP in the production of therapeutic protein drugs. Now, with the continuous improvement and upgrading of technology, liquid ...
Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics. “While microneedle technology is not new, our company represents the evolution of the technology over many years,” Steven Damon, CEO, says in an interview with BioTuesdays.com. “We’re developing an innovative ...
Durham, NC (April 28, 2020) - A review article published in PNAS highlights Symberix's efforts to understand the role of the human microbiota in drug efficacy and toxicity. Symberix co-founder Matt Redinbo is featured in the article alongside other leaders from the emerging field of “pharmacomicrobiomics” -- the study of mechanisms behind the microbial impact on drug metabolism. ...
Durham, NC (February 3, 2020) - An article in Nature highlights Symberix's efforts to understand the complex relationship between drugs and the microbiome. The paper discusses recent contributions to the emerging field of “pharmacomicrobiomics” -- the study of how microbes impact drug disposition, efficacy, and toxicity. Symberix is developing bacteria-targeted small molecules that ...
As regulators focus in on the critical quality attributes (CQAs) of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations assays – other than to run additional orthogonal assays? Many labs are finding the answer in mass detection, specifically with the ACQUITY QDa Detector from Waters. Here are three ways that mass ...
This paper analyses which organisational and industrial factors influence the chance that a US biopharmaceutical start-up is able to introduce a new drug on the US market. Specific attention is paid to the critical mass a biotech company should obtain to improve its chances of bringing a new drug to the market. In the same vein, the economies of scale in R&D are taken into consideration. Second, ...